2 results match your criteria: "Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias[Affiliation]"
Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease.
Med Clin (Barc)
February 2023
Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, Tenerife, Spain.
Introduction: Monitoring plasma levels of Infliximab plays an important role in optimising treatment in patients with inflammatory bowel disease (IBD). The aim of the following study has been to determine the predictive potential of monitoring infliximab plasma levels for sustained clinical response and evaluate its usefulness to improve treatment efficacy and symptom control, in patients with IBD.
Methods: This single-centre retrospective study (2017-2019) included patients diagnosed with IBD treated with infliximab.
[Adequacy to diagnostic recommendations in patients with Pneumocystis jirovecii pneumonia treated with intravenous pentamidine].
Rev Esp Quimioter
February 2022
Lorenzo Cantarelli, Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, Tenerife (España). Carretera Ofra s/n, La Laguna (Tenerife); Spain.
Objective: To determine the rate of microbiological confirmation in the diagnosis of Pneumocystis jirovecii pneumonia in patients treated with intravenous pentamidine and the potential correlation with treatment effectiveness and safety.
Methods: Single-centre retrospective study (2010-2020), which included those patients who received intravenous pentamidine treatment for at least 48 hours. The sample collection procedure and the microbiological analysis performed were recorded.